RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

The RAPS store will be under maintenance Saturday, 6 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > Avoiding Major Reasons for a Clinical Hold by FDA

Avoiding Major Reasons for a Clinical Hold by FDA

Posted 01 January 2009 | By William Sietsema, PhD

The term "clinical hold" can strike fear into the heart of even the most seasoned regulatory professional. It is not always possible to avoid these difficult situations, but well-prepared project teams are able to anticipate potential issues with the US Food and Drug Administration (FDA) and can understand and manage the risks. This article reviews regulations related to clinical holds, and then discusses the most common reasons for clinical holds, grouped by chemistry, human efficacy and safety, and pharmacology/toxicology, and discusses the impact of a pre-IND meeting on the probability of a clinical hold.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe